
Becton, Dickinson and Company (NYSE:BDX) has agreed to combine its Biosciences & Diagnostic Solutions business with Waters Corporation (NYSE:WAT).
The agreement is structured as a tax-efficient Reverse Morris Trust transaction valued at approximately $17.5 billion. The transaction is expected to close around the end of the first quarter of calendar year 2026.